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ABSTRACT 
 
This study was conducted to investigate the 
incidence of community acquired extended-
spectrum β-lactamase (ESBL)-producing bacteria 
among asymptomatic students of Nnamdi Azikiwe 
University, Awka, Anambra State, South-East 
Nigeria. A total of 102 non-duplicate strains of 
Escherichia coli, Klebsiella pneumoniae and 
Pseudomonas aeruginosa were isolated from fecal 
samples (n=273) collected from the participating 
students. The isolates were subjected to 
antimicrobial susceptibility tests to determine their 
antimicrobial resistance profile. Their multiple 
antibiotic resistance (MAR) indices were also 
evaluated.  Screening of the isolates for possible 
ESBL production was carried out by disk diffusion 
test using cefotaxime and ceftazidime disks. ESBL-
production by the resistant strains was confirmed 
using the double-disk synergy test. Most of the 
isolates were found to be multi-drug resistant, as all 
K. pneumoniae and P. aeruginosa strains (100%), 
and 98.4% of the E. coli strains, had MAR indices 
≥0.2. A total of 22 ESBL-producing bacterial 
species were confirmed, and the frequency of                 
E. coli, K. pneumoniae and P. aeruginosa isolates 
among the ESBL-producing bacteria were n=20 
(90.9%), n=2 (9.1%), and n=0 (0.0%) respectively. 
The total number of ESBL-producing bacterial 
strains isolated accounted for 8.1 % of the entire 
sample population. Although this prevalence rate 
may not indicate an alarming situation, it is 
important that the proliferation of ESBL-producing 
bacteria in the community be contained, since a high 
incidence of ESBL-producing organisms will create 
significant therapeutic problems in the near future. 
There is therefore need to develop strategies to 
reduce their spread in the community especially 
through monitoring, surveillance and proper 
detection protocol. 
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1. INTRODUCTION 
 
 β-lactamases are the most common mecha-
nism of resistance to beta-lactam antibiotics inclu-
ding the third-generation cephalosporins to which 
extended spectrum β-lactamase plays a huge role 
among Enterobacteriaceae [1, 2]. Though there are 
different diverse β-lactamases, the extended spec-
trum β-lactamases (ESBLs) have been known to be 
of very high clinical importance. Infections caused 
by ESBL-producing organisms are difficult to 
manage for several reasons. First, empiric therapy 
consisting of β-lactam antimicrobials is often 
ineffective; and second, these organisms tend to also 
be resistant to other classes of antimicrobials inclu-
ding fluoroquinolones and aminoglycosides [1].   
 ESBLs capable of degrading the cephalo-
sporins and monobactams are among the most 
important resistance determinants emerging in 
Enterobacteriaceae worldwide. ESBLs are β-lacta-
mases capable of conferring bacterial resistance to 
the penicillins, first-, second-, and third-generation 
cephalosporins, and aztreonam by hydrolysis, 
excluding the cephamycins and carbapenems. These 
enzymes hydrolyze extended-spectrum cephalo-
sporins such as ceftazidime or cefotaxime, as well            
as monobactams (aztreonam), and are inhibited by  
β-lactamase inhibitors [1, 3-5].   
 ESBLs have been reported worldwide in 
many different genera of Enterobacteriaceae and 
Pseudomonas aeruginosa. However, ESBL produc-
tion has been previously reported to be most 
common in Klebsiella spp. and Escherichia coli              
[6-8]. It has become very important to study the 
prevalence of ESBL-producing organisms because 
of their increasing antimicrobial resistance and the 
decreasing number of new drugs available against 
such organisms.  
 Though the first detection of ESBLs in 
Nigeria is still not known and a national study for 
the actual prevalence of ESBL-producing bacteria in 
Nigeria is lacking, some reports have shown the 
increasing prevalence of ESBL-producing bacteria 
in some parts of the country [9-18]. 
 The implications of the prevalence of ESBL-
producing organisms in Nigerian communities 
cannot be overlooked. The wide and irrational               
use of antibiotics, especially the broad spectrum            
β-lactams, in our local communities allow for the 
emergence and spread of resistant strains of bacteria 
that render available drugs ineffective for treatment. 
Keeping in view the economic and clinical impor-
tance of ESBL-producing bacteria, our study was 
conducted to investigate the incidence of community 
acquired ESBL-producing bacteria among healthy 
and asymptomatic university students in Anambra 
State, South-East Nigeria. 
 
2. MATERIALS AND METHODS 
 
2.1. Study area and population 
 
 The study population comprised of students  
of Nnamdi Azikiwe University studying at the 
university campuses located at Agulu, Mbaukwu 
and Awka, Anambra State, Nigeria. The participants 
were adult male and female students between the 
ages of 18-26 years. Inclusion criteria were: (1) the 
participant is ≥18 years; (2) healthy or appear 
healthy at physical examination; (3) have no history 
of previous ESBL infection; (4) have not been 
hospitalized in the last 6 months. Consent forms and 
questionnaires indicating demographics and medical 
history of the individual were filled by the 
participating students. 
 
2.2. Collection of samples 
 
 A total of 273 stool samples were randomly 
collected over a twelve (12) month period (March 
2012-February 2013) from consenting university 
students spread across the three campuses of the 
university. 
 
2.3. Isolation and identification of microorga-
nisms 
 
 For bacterial isolation and identification, 
various cultural, staining, and biochemical testing 
procedures were carried out as previously described 
[19, 20]. A loopful of each stool sample was 
inoculated into respective test tubes containing                      
5 ml of freshly prepared nutrient broth (Oxoid,           
UK) and incubated at 35°C for 24 h. Bacterial 
growth was indicated by the turbidity of the               
broth culture. Using a wire loop, suspensions from 
the turbid solution was plated aseptically onto 
MacConkey and cetrimide selective agars (Oxoid, 
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UK) plates and incubated at 35°C for 24 h. 
Suspected colonies of Escherichia coli and Kleb-
siella pneumoniae isolates were subcultured onto 
freshly prepared MacConkey agar plates, while 
suspected Pseudomonas aeruginosa isolates were 
subcultured onto cetrimide selective agar plates to 
obtain pure cultures. For confirmation, Gram 
staining and con-ventional biochemical testing 
techniques including indole test for suspected E. 
coli, citrate and malonate utilization tests for 
suspected K. pneumoniae, and oxidase test for 
suspected P. aeruginosa were carried out. 
 
2.4. Antimicrobial Susceptibility Test (AST) 
 
 AST of the isolates was carried out using             
the modified Kirby-Bauer disk diffusion method 
described by Cheesbrough [19] and the Clinical and 
Laboratory Standard Institute (CLSI) [21]. Mueller-
Hinton (MH) agar (Oxoid, UK) was prepared accor-
ding to the manufacturer’s instructions, and trans-
ferred into 90 mm diameter sterile Petri dishes to             
a depth of 4 mm. The surface was lightly and 
uniformly inoculated using a sterile cotton wool 
swab in three directions rotating the plate appro-
ximately 600C, to ensure even distribution. Prior to 
inoculation, the swab stick was dipped into bacterial 
suspension having visually equivalent turbidity to 
0.5 McFarland standards. Excess liquid from the 
sterile cotton-wool swab dipped in the bacterial 
suspension was removed by turning the swab stick 
against the side of the tube.  The plates were covered 
and allowed to dry on the bench before applying the 
discs. Antibiotic discs were placed on the agar plate 
within 15 minutes of inoculation of isolates. 
Inoculated plates were incubated at 37 oC for 24 
hours. On the next day, plates were read by             
taking measurement of zone of inhibition using a 
meter rule; E. coli ATCC 25922 was used as a 
negative control. Antibiotic disks used include 
cefotaxime (30 µg), ceftazidime (30 µg), ceftriaxone 
(30 µg), imipenem (10 µg), meropenem (30 µg), 
tetracycline (30 µg), erythromycin (15 µg), 
cefpodoxime (10 µg), amoxycillin-clavulanic acid 
(20/10 µg), sulphamethoxazole-trimethoprim (25 
µg), ciprofloxacin (5 µg), and gentamicin (10 µg) 
(Oxoid, UK). 
 
2.5. Screening of bacterial isolates for possible 
ESBL production 
 
 To screen all the E. coli, K. pneumoniae            
and P. aeruginosa isolates for the production of 
ESBL enzymes, single antibiotic disks comprising 
cefotaxime (30 µg) and ceftazidime (30 µg) were 
placed aseptically at a distance of 30 mm apart on 
MH agar plates that was previously swabbed with 
standardized inoculum of the test bacterium. The 
plates were allowed for about 30 mins for pre-
diffusion of the antibiotics; and these were incubated 
for 18-24 hrs at 37oC. After the incubation, the 
zones of inhibition were measured and recorded             
to the nearest millimeter using a meter rule.            
ESBL production was inferred or suspected if any of 
the test bacteria showed reduced susceptibility or          
is resistant to any one of the third generation 
cephalosporins (cefotaxime and ceftazidime) as per 
the breakpoints of CLSI [21]. 
 
2.6. Multiple Antibiotic Resistance (MAR) Index 
 
 Multiple antibiotic resistance (MAR) index 
(number of antibiotics to which test isolate displayed 
resistance divided by total number of antibiotics to 
which the test organism has been evaluated for 
sensitivity/resistance) for each test isolate was 
calculated according to the method described by 
Riaz et al. [22]. 
 
2.7. Confirmation of ESBL production by Double 
Disk Synergy Test (DDST) 
 
 ESBL production was confirmed in the                
E. coli, K. pneumoniae and P. aeruginosa isolates 
by the double disk synergy test (DDST) method as 
previously described [21]. DDST was performed as 
a standard disk diffusion assay on MH agar plates. 
Standardized bacteria suspension was aseptically 
swabbed on the MH agar plates. Amoxycillin-
clavulanic acid disc (20/10 µg) was placed at the 
centre of the plate, and cefotaxime (30 µg) and 
ceftazidime (30 µg) discs were each placed at a 
distance of 15 mm (centre to centre) from the 
amoxycillin-clavulanic acid disc. The plates were 
incubated at 37oC for 18-24 hrs. ESBL production 
was confirmed phenotypically when a difference of 
≥5 mm increase in the inhibition zone diameter for 
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the zones of inhibition of the cephalosporins 
(cefotaxime and ceftazidime) tested alone and in 
combination with amoxicillin-clavulanic acid was 
observed. 
 
3. RESULTS 
 
3.1. Isolation and identification of microorga-
nisms 
 
 A total of 273 fecal samples from the 
university students were analyzed. Of the 273 
samples analyzed, 102 non-duplicate bacterial 
isolates comprising E. coli (n=63), K. pneumoniae 
(n=20), and P. aeruginosa (n=19) were isolated.  
 
3.2. Antimicrobial resistance profile of the 
community-derived isolates 
 
 The E. coli isolates showed high resistance of 
76.2, 82.5, and 79.3% to cefpodoxime, tetracycline, 
and erythromycin respectively. The E. coli isolates 
showed least resistance to imipenem (6.3%) 
followed by ciprofloxacin (14.3%) and cefotaxime 
(14.5%). All P. aeruginosa isolates were completely 
resistant (100%) to cefpodoxime, meropenem, 
amoxicillin-clavulanic acid and erythromycin, but 
were highly susceptible to imipenem, gentamicin 
and ciprofloxacin with a percent resistance of 5%. 
K. pneumoniae isolates like P. aeruginosa showed 
complete resistance (100%) to cefpodoxime, and 
were highly resistant to meropenem (90%), 
sulfamethoxazole-trimethoprim (75%), tetracycline 
(85%) and erythromycin (90%). Generally, imi-
penem showed the highest antibacterial activity 
against the tested isolates, followed by ciprofloxacin 
and gentamicin (Table 1). It can be observed in 
Table 2 the isolates were found to be multi-drug 
resistant as all K. pneumoniae and P. aeruginosa 
strains (100%), as well as 98.4% of the E. coli 
strains had MAR indices of 0.2 and above. 
  
 
Table 1. Antibiotic resistance profile of isolates. 
Antibiotics 
Resistance (%) 
E. 
coli 
K. 
pneumoniae 
P.  
aeruginosa 
Ceftazidime 20.6 30 11 
Cefotaxime 14.5 25 32 
Ceftriaxone 34.9 25 16 
Cefpodoxime 76.2 100 100 
Imipenem 6.3 0 5 
Meropenem 58.7 90 100 
Amoxycillin-
clavulanic acid 28.6 40 100 
Gentamicin 20.6 15 5 
Ciprofloxacin 14.3 15 5 
Sulfamethoxazole
-trimethoprim 54 75 84 
Tetracycline 82.5 85 79 
Erythromycin 79.3 90 100 
 
 
 
           Table 2. Multiple Antibiotic Resistance (MAR) Index of isolates. 
Frequency of MAR Index 
MAR Index E. coli 
n (%) 
K. pneumoniae 
n (%) 
P. aeruginosa 
n (%) 
0 (0.00%) 0 (0.00%) 0 (0.00%) 0 
1 (1.59%) 0 (0.00%) 0 (0.00%) 0.1 
13 (20.63%) 1 (5.00%) 0 (0.00%) 0.2 
17 (26.98%) 1 (5.00%) 1 (5.27%) 0.3 
12 (19.05%) 7 (35.00%) 3 (15.79%) 0.4 
15 (23.81%) 7 (35.00%) 10 (52.63%) 0.5 
5 (7.94%) 4 (20.00%) 4 (21.05%) 0.6 
0 (0.00%) 0 (0.00%) 0 (0.00%) 0.7 
0 (0.00%) 0 (0.00%) 0 (0.00%) 0.8 
0 (0.00%) 0 (0.00%) 0 (0.00%) 0.9 
0 (0.00%) 0 (0.00%) 1 (5.26%) 1.0 
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3.3. Confirmation of ESBL-producing isolates 
 
 DDST was used for the phenotypic confir-
mation of ESBL production by the isolates. An 
increase of ≥5 mm was observed in the IZDs 
produced by the cephalosporins (with amoxicillin-
clavulanic acid) against the ESBL producing 
organisms compared to the individual IZDs of               
any of the cephalosporins (without amoxicillin-
clavulanic acid) (Figure 1). This was consistent with 
the CLSI’s specifications for the double disc 
synergy test for the confirmation of ESBL 
production [21]. 
 A total number of 102 Gram negative iso-
lates (encompassing E. coli, K. pneumoniae, and            
P. aeruginosa) were isolated from the sample 
population (n=273). From these isolates, 22 ESBL-
producing bacteria strains were confirmed, which              
is 8.1% of the total sample population. Of the          
total number of Gram negative isolates (n=102), 
21.6% (n=22) were confirmed ESBL-producers. A 
majority of the ESBL-producers were E. coli (n=20, 
90.9%), followed by K. pneumoniae (n=2, 9.1%). 
ESBL-production was not detected among the                
P. aeruginosa isolates (Figure 2).  
 
 
 
 
Figure 1. A picture of ESBL-producing isolate after the double-disc synergy testing 
(DDST); showing the keyhole effect notable for ESBL production in the phenotypic test. 
 
 
 
Figure 2. Total ESBL-producers and non-ESBL-producers among the community isolates. 
 
 
3.4. Geographic and gender distribution of the 
samples, total isolates and ESBL-producing 
isolates 
 
 A total number of 273 samples were collec-
ted from the three locations Agulu, Awka, and 
Mbaukwu. The highest percentage of the samples 
came from Agulu (63.4%), followed by Mbaukwu 
(24.5%) and Awka (12.1%) (Table 3). A total of  
102 non-duplicate bacterial isolates comprising of  
K. pneumoniae, E. coli and P. aeruginosa strains 
were isolated from the samples; and 52.0%, 17.6%, 
and 30.4% of the total number of isolates were          
from Agulu, Awka and Mbaukwu respectively. The 
distribution of the ESBL-producing bacteria from 
the three locations follows the same pattern as the 
distribution of the total number of samples and 
isolates from the locations.  
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Table 3. Geographical distribution of samples, total isolates and ESBL-producing isolates. 
Source of 
samples 
Number of 
samples 
[n (%)] 
Number of isolates  
[n (%)] 
Number of ESBL-producing isolates  
[n (%)] 
EC KP PA Total EC KP PA Total 
Agulu 173  (63.4%) 
43  
(42.15%) 
9  
(8.82%) 
1  
(1.0%) 
53  
(52.0%) 
16  
(72.7%) 
0  
(0.0%) 
0  
(0.0%) 
16 
(72.7%) 
Awka 33  (12.1%) 
7  
(6.86%) 
3  
(2.94%) 
8  
(7.8%) 
18  
(17.6%) 
0  
(0.0%) 
2  
(100.0%) 
0  
(0.0%) 
2  
(9.1%) 
Mbaukwu 67  (24.5%) 
13  
(12.74%) 
8  
(7.84%) 
10  
(9.8%) 
31  
(30.4%) 
4  
(18.2%) 
0  
(0.0%) 
0  
(0.0%) 
4  
(18.2%) 
Total 273  (100.0%) 
63  
(100.0%) 
20  
(100.0%) 
19  
(100.0%) 102 (100.0%) 
20  
(100.0%) 
2  
(100.0%) 
0  
(0.0%) 
22  
(100.0%) 
KP: K. pneumoniae, EC: E. coli, PA: P. aeruginosa. 
 
 
Table 4. Gender distribution of samples, total isolates and ESBL-producing isolates. 
Gender 
Gender distribution of samples collected 
[n (%)] 
Gender distribution of isolated bacteria 
[n (%)] 
Gender distribution of ESBL-producing 
isolates 
[n (%)] 
Agulu Awka Mbaukwu Total EC KP PA Total EC KP PA Total 
Males 41  (23.7%) 
20  
(60.6%) 
17 
(25.4%) 
78 
(28.6%) 
22 
(34.9%) 
8 
(40.0%) 
7 
(36.8%) 
37 
(36.3%) 
2 
(10.0%) 
1 
(50.0%) 
0 
(0.0%) 
3 
(13.6%) 
Females 122 (64.7%) 
10  
(30.3%) 
41 
(61.2%) 
173 
(63.4%) 
35 
(55.6%) 
10 
(50.0%) 
11 
(57.8%) 
56 
(54.9%) 
16 
(80.00%) 
1 
(50.0%) 
0 
(0.0%) 
17 
(77.3%) 
Unknown 10 (5.8%) 
3 
(9.1%) 
9 
(13.4%) 
22 
(8.1%) 
6 
(9.5%) 
2 
(10.0%) 
1 
(5.3%) 
9 
(8.8%) 
2 
(10.0%) 
0 
(0.0%) 
0 
(0.0%) 
2 
(9.1%) 
Total 173 (100.0%) 
33 
(100.0%) 
67 
(100.0%) 
273 
(100.0%) 
63 
(100.0%) 
20 
(100.0%) 
19 
(100.0%) 
102 
(100.0%) 
20 
(100.0%) 
2 
(100.0%) 
0 
(0.0%) 
22 
(100.0%) 
KP: K. pneumoniae, EC: E. coli, PA: P. aeruginosa. 
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 As more samples were collected from Agulu 
(n=173, 63.4%), followed by Mbaukwu (n=67, 
24.5%), and then Awka (n=33, 12.1%), the highest 
percentage of ESBL-producing isolates was from 
Agulu (n=16, 72.7%), followed by Mbaukwu (n=4, 
18.2%), and then Awka (n=2, 9.1%). Of the 22 
ESBL-producing isolates, E. coli was the most 
prevalent (n=20, 90.9%), followed by K. pneumo-
niae (n=2, 9.1%). No ESBL-producing P. aerugi-
nosa strain was detected. A rate of 72.7% of the            
E. coli isolates that were found to be ESBL-produ-
cers were isolated from Agulu, 18.2% were from 
Mbaukwu, and none from Awka. ESBL-producing 
K. pneumoniae (n=2, 100%) was reported only from 
samples emanating from Awka (Table 3). 
 Of the total 273 fecal samples collected from 
the university students, 173 (63.4%) samples were 
received from female students, and 78 (28.6%) were 
from male students. Twenty two (8.1%) students           
did not indicate their genders (Table 4). A total               
of 36.3% of all the bacterial isolates comprising               
K. pneumoniae, E. coli and P. aeruginosa strains 
were from males, and 54.9% were from females. 
The distribution of the ESBL-producing bacteria 
amongst the female and male students also follows 
the same pattern as the distribution of the total 
number of samples and isolates amongst the male 
and female students.  
 As more samples were collected from the 
female participants (n=173, 63.4%) compared to 
their male counterparts (n=78, 28.6%), the highest 
percentage of ESBL-producing isolates was from 
the female students (77.3%), while 13.6% was 
recorded for the male students. Eighty percent of   
the E. coli isolates that were found to be ESBL-
producers were isolated from the female students, 
and 10.0% were from the males. There was an equal 
distribution of ESBL-producing K. pneumoniae 
(50%) amongst the female and male students         
(Table 4). 
 
4. DISCUSSION 
 
 The antibiotic resistance profile of the isolates 
reveals that the isolates were generally resistant to 
the different classes of antibiotics tested. The 
isolates however, exhibited very high resistance 
rates to cefpodoxime, meropenem, tetracycline, 
erythromycin, and sulfamethoxazole-trimethoprim. 
Lower levels of resistance to ciprofloxacin and 
gentamicin were recorded among the community 
isolates. The isolates showed least resistance only              
to imipenem, a drug known for its potent and            
broad spectrum antimicrobial activity. The complete 
susceptibility of the isolates to imipenem could be 
attributed to the low-rate use of the drug, since is 
extremely expensive and not readily available in the 
Nigerian market, and is used as a last option in 
serious infections when all other antimicrobial drugs 
have failed. 
 Majority of the isolates were found to be 
multi-drug resistant with MAR index ≥2 (Table 2). 
Riaz et al. [22] stated that a MAR index >0.2 
indicates that the organism may have originated 
from an environment where antibiotics are over 
used. The observed resistance to these drugs is a 
probable indication of earlier exposure of the 
isolates to the antibiotics, which may have enhanced 
their multidrug-resistance development.  
 From the 102 Gram negative bacteria isolated 
from the sample population (n=273), a total number 
of 22 (8.1 %) ESBL-producing bacteria strains were 
confirmed. The ESBL-producing isolates observed 
in this study were E. coli and K. pneumoniae. This is 
in agreement with other studies that reported the 
expression of the ESBL enzyme by both species [1, 
23, 24]. 
 Tansarli et al. [7] indicated that Nigeria, 
together with several other African countries with 
low human development index (Rwanda, Kenya, 
Nigeria, Central African Republic, Benin, Senegal, 
Malawi and Tanzania), have prevalence rates of  
ESBL-producing organisms from both clinical or 
community sources varying from 3.8% to 22.8%. 
Their report showed that the proportion of ESBL-
producing isolates among the Enterobacteriaceae 
may not be high in Africa, but is certainly not 
negligible [7].  
 The 8.1% prevalence rate of ESBL-producing 
organisms in our study population may not indicate 
an alarming situation, but there is need for it to             
be curtailed since a high incidence of ESBL-produ-
cing organisms will create significant therapeutic 
problems in the near future. 
 Several studies in Nigeria have shown that 
abuse and indiscriminate use of antibiotics by people 
practicing self-medication are partly responsible for 
the high prevalence of multidrug resistance and 
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ESBL-producing bacteria in both community and 
hospital acquired infections [18, 25, 26]. In our 
study, majority of the study participants indicated 
that they have at one time or the other taken 
antibiotics without prescription, especially for 
ailments such as, typhoid, UTI, cough, and sore 
throat to mention a few. It can be inferred that the 
occurrence of multidrug-resistant and ESBL-produ-
cing bacteria among the university students may             
be attributed to the abuse and indiscriminate use            
of antibiotics by the students in this region. In 
Nigeria, antibiotics can be relatively inexpensive, 
sold usually over the counter even without pres-
cription, and can be readily abused or used indiscri-
minately. Moreover, the indiscriminate proliferation 
of patent medicine outlets that makes these drugs 
easily accessible in the community, as observed in 
the study locations, may have also contributed to the 
proliferation of these resistant bacteria in the 
community. This should be of great health concern 
to university communities across Nigeria, as well as 
the entire Nigerian population. 
 ESBL detection and prevalence studies in 
Nigeria are majorly undertaken by researchers in the 
academia. However, this have been quite limited to 
the educational/research institutions without the 
translation of the findings into a template that can be 
used in our hospitals for the accurate detection of 
ESBL from clinical isolates, as well as for the 
development of policies that will guide the 
proliferation, use, and abuse of antibiotics in the 
non-hospital environment.  
 According to Shaikh et al. [27] and Coque et 
al. [28], the detection of ESBL production is of 
paramount importance both in hospital and com-
munity isolates. Therefore, infection-control practi-
tioners and clinicians need the clinical laboratory to 
rapidly identify and characterize different types of 
resistant bacteria. Methods should be improved to 
efficiently detect and track those bacterial clones 
and plasmids that constitute the major vehicles               
for the spread of ESBL-mediated resistance. An 
improvement is needed in the methods for detecting 
multidrug-resistant ESBL producers that express a 
low level of resistance to β-lactams or might contain 
silenced antibiotic resistance genes not detectable by 
standard susceptibility testing protocols. The use of 
broad spectrum cephalosporins and fluoroquino-
lones in humans should be urgently limited to cases 
in which other therapeutic alternatives according to 
evidence-based guidelines are not possible. Limiting 
antimicrobial use may curtail the selection and 
persistence of predominant ESBL clones and the 
probable dissemination of conjugative plasmids 
among strains, thus decreasing not only the number 
of potential ESBL donors but also the accumulation 
of antibiotic resistance genes on common genetic 
elements. There is also need for national and supra-
national public health efforts to implement 
surveillance, epidemiologic, environmental health, 
and policy-making components on the use of 
antibiotics. These will certainly contain the spread 
of ESBL-producing organisms and prevent the 
emergence of new incidences of diseases caused by 
ESBL-producing organisms. 
 
5. CONCLUSION 
 
 This study has revealed the presence of 
multidrug-resistant, ESBL-producing organisms 
among healthy university students of Nnamdi 
Azikiwe University community, Anambra State, 
Nigeria. The proliferation of ESBL-producing 
organisms in the community will create significant 
therapeutic problems in the near future if not 
curtailed. There is need to develop effective and 
innovative strategies to reduce their spread in the 
community. 
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